Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Biotech Bonanza! -- Ignore unavailable to you. Want to Upgrade?

To: F. Jay Abella, III who wrote (29)	10/29/1997 12:30:00 PM
From: Giuseppe Scalamogna	Read Replies (2) \| Respond to of 64

FJA Your risk assessment is right on. They mitigate the risk through a three tier strategy with tier 1 being currently marketed generic and anticancers, tier 2 being Supergenerics and tier 3 being propietary new treatments such as those for obesity and RFS 2000. What does this tell me? Well it seems to indicate that the company prefers stability to blockbuster success although that may come along the way. Cash burn for the company is mitigated in a layer strategy which eventually will lead to profitability, I'm thinking in or about Q4 of 1998. Nipent will continue to produce operating revenues along with the anticancers from Barr and Immunex. I think that was and still is the primary focus of Tier 1. The company has gone through some equity financing but that will end very soon as the company pumps Extra formulations up to full scale and expands sales of Nipent. With achievement of tier 1 and tier 2 products, the company has diminished risk associated with tier 3 to a much more tolerable level. I do believe that with completion of tier 1 & 2, not only will the company be profitable but will be in a position to expend capital for their own manufacturing facilities by which they can tap into their proprietary fermentation process to expand margins on the pipeline of those products. You are right FJA, the management really does know the drug business and is tackling the biggest problem associated with it; risk. I will comment on Capital Structure soon. GS PS - In regards to the next company to present, I am not familiar with SunPharm but will be happy to take a look at it. When we begin discussion of SunPharm on Monday, November 10, 1997 we can present the next stock at that time, so everyone can be prepared to discuss after discussion of Sunpharm comes to an end.